ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.83 Million CAD | 41.13% |
| 2022 | -4.8 Million CAD | -42.68% |
| 2021 | -3.36 Million CAD | -15.1% |
| 2020 | -2.92 Million CAD | -34.08% |
| 2019 | -2.18 Million CAD | 5.29% |
| 2018 | -2.3 Million CAD | -28.96% |
| 2017 | -1.78 Million CAD | -68.46% |
| 2016 | -1.06 Million CAD | -60.2% |
| 2015 | -662.34 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 5000.00 CAD | 100.67% |
| 2024 Q2 | -216 Thousand CAD | -4420.0% |
| 2023 Q3 | -357 Thousand CAD | -61030.14% |
| 2023 Q1 | -1.05 Million CAD | 10.03% |
| 2023 Q2 | -584.00 CAD | 99.94% |
| 2023 Q4 | -743 Thousand CAD | -108.12% |
| 2023 FY | -2.83 Million CAD | 41.13% |
| 2022 Q2 | -1.12 Million CAD | -88028.93% |
| 2022 FY | -4.8 Million CAD | -42.68% |
| 2022 Q4 | -1.17 Million CAD | 3.13% |
| 2022 Q3 | -1.21 Million CAD | -8.3% |
| 2022 Q1 | -1272.00 CAD | -60.81% |
| 2021 Q4 | -791.00 CAD | 20.18% |
| 2021 Q1 | -903 Thousand CAD | 7.29% |
| 2021 Q2 | -572.00 CAD | 99.94% |
| 2021 Q3 | -991.00 CAD | -73.25% |
| 2021 FY | -3.36 Million CAD | -15.1% |
| 2020 Q4 | -974 Thousand CAD | -53.63% |
| 2020 FY | -2.92 Million CAD | -34.08% |
| 2020 Q3 | -634 Thousand CAD | -47.44% |
| 2020 Q1 | -892 Thousand CAD | -154.86% |
| 2020 Q2 | -430 Thousand CAD | 51.79% |
| 2019 FY | -2.18 Million CAD | 5.29% |
| 2019 Q4 | -350 Thousand CAD | 45.14% |
| 2019 Q3 | -638 Thousand CAD | -6.51% |
| 2019 Q2 | -599 Thousand CAD | -14.75% |
| 2019 Q1 | -522 Thousand CAD | 25.83% |
| 2018 Q2 | 445.13 Thousand CAD | 209.32% |
| 2018 Q1 | -407.2 Thousand CAD | 29.27% |
| 2018 Q3 | -748.89 Thousand CAD | -268.24% |
| 2018 Q4 | -703.81 Thousand CAD | 6.02% |
| 2018 FY | -2.3 Million CAD | -28.96% |
| 2017 FY | -1.78 Million CAD | -68.46% |
| 2017 Q1 | -175.38 Thousand CAD | -7.78% |
| 2017 Q2 | -382.84 Thousand CAD | -118.29% |
| 2017 Q3 | -596.09 Thousand CAD | -55.7% |
| 2017 Q4 | -575.68 Thousand CAD | 3.42% |
| 2016 Q2 | -348.87 Thousand CAD | -29.1% |
| 2016 FY | -1.06 Million CAD | -60.2% |
| 2016 Q4 | -162.71 Thousand CAD | 41.72% |
| 2016 Q1 | -270.24 Thousand CAD | 33.36% |
| 2016 Q3 | -279.21 Thousand CAD | 19.97% |
| 2015 Q2 | -53.58 Thousand CAD | -46.68% |
| 2015 FY | -662.34 Thousand CAD | 0.0% |
| 2015 Q4 | -405.54 Thousand CAD | -143.3% |
| 2015 Q1 | -36.53 Thousand CAD | 0.0% |
| 2015 Q3 | -166.68 Thousand CAD | -211.07% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -5.01 Million CAD | 43.604% |
| Asep Medical Holdings Inc | -7.72 Million CAD | 63.348% |
| BetterLife Pharma Inc. | -3.24 Million CAD | 12.661% |
| BioVaxys Technology Corp. | -2.4 Million CAD | -17.789% |
| Rapid Dose Therapeutics Corp. | -3.73 Million CAD | 24.307% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 77.639% |
| Entheon Biomedical Corp. | -313.99 Thousand CAD | -801.297% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 44.356% |
| Glow Lifetech Corp. | -1.64 Million CAD | -72.276% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | -319.434% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | -270.929% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | -649.405% |
| MYND Life Sciences Inc. | -1.8 Million CAD | -56.546% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -135.382% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 7.033% |
| PreveCeutical Medical Inc. | -963.12 Thousand CAD | -193.835% |
| Telescope Innovations Corp. | -5.76 Million CAD | 50.926% |